Impact ledger
Amgen Inc. (AMGN): the developments shaping its investment case
Follow the evidence affecting Amgen Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Amgen Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-17
Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
Channel: Validation of novel therapeutic approaches, potential for future pipeline expansion or partnerships in cardiovascular diseases, especially given their existing cardiovascular portfolio.
Bullish· 1-3m
2026-09-18 · 6 reports
Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary
Channel: Increased competitive pressure in the obesity and metabolic disease space, potentially diverting R&D focus or market share from existing or pipeline products.
Bearish· 3-12m
2026-09-23 · 2 reports
Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
Channel: Increased competitive landscape for next-generation obesity drugs, potentially diminishing the perceived value and market opportunity for Amgen's own pipeline assets (e.g., AMG 133).
Bearish· 3-12m
Event impact log
73 events mapped to AMGN since 2026-08-12. Evidence through 2026-09-28.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-28 | Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocation | Competitive landscape dynamics, R&D strategy, and investor sentiment towards GLP-1 market participants. | watch | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly discontinues pipeline GLP-1 candidate following efficacy review | Indirect competitive landscape effect. Reduced potential future competition in the GLP-1 space. | Bullish | 3-12m | 0.10 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | Potential future competition in oncology, specifically for KRAS targets, if HMPL-A830 progresses. | watch | 1-5y | 0.20 |
| 2026-09-28 | Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise lead | Competitive landscape, investor perception of pipeline strength in obesity/metabolic disorders. | mixed | 3-12m | 0.20 |
| 2026-09-28 | Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy Review | Reduced potential future competition in the GLP-1 market; relative strengthening of other pipeline candidates. | Bullish | 1-3m | 0.10 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of Sales | Competitive landscape, R&D pipeline comparison, investor sentiment | Bullish | 3-12m | 0.30 |
| 2026-09-28 | Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulations | Competitive landscape, R&D focus, market sentiment | mixed | 3-12m | 0.30 |
| 2026-09-28 | Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy Data | Reduced future competitive pressure in the GLP-1 market from a major rival's pipeline, potentially improving the competitive outlook for other pipeline assets. | Bullish | 3-12m | 0.40 |
| 2026-09-28 | HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate | Potential competitive pressure in the KRAS inhibitor market, particularly for novel mechanisms. | watch | 1-5y | 0.20 |
| 2026-09-27 | Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total Revenue | Reduced future competitive pressure in the obesity market, potentially enhancing the long-term outlook for its own obesity pipeline assets. | Bullish | 3-12m | 0.30 |
| 2026-09-27 | Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% Revenue | Indirect competitive advantage. Reduced future competition in the obesity market, potentially increasing the value of their own pipeline assets. | Bullish | 1-5y | 0.30 |
| 2026-09-27 | Eli Lilly discontinues developmental obesity drug over unmet efficacy threshold | Indirectly, as a major pharmaceutical company with its own R&D pipeline, this event could lead to increased investor scrutiny on the efficacy and diversification of other companies' developmental assets, particularly in competitive therapeutic areas. | watch | 3-12m | 0.30 |
| 2026-09-27 | Eli Lilly Drops Experimental Obesity Candidate While Core GLP-1s Exceed 65% of Revenue | Increased scrutiny on the obesity drug pipeline and R&D efficiency across the industry, potentially impacting investor sentiment towards companies with early-stage or unproven metabolic assets. | watch | 3-12m | 0.30 |
| 2026-09-27 | Eli Lilly Discontinues Developmental GLP-1 Candidate Over Efficacy Standards | Competitive landscape and R&D strategy in the metabolic space. The event emphasizes the difficulty of developing competitive GLP-1s, which could be seen as both a challenge and an opportunity for companies with different mechanisms of action or later-stage candidates. | mixed | 3-12m | 0.30 |
| 2026-09-26 | C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data | Potential future competition in the multiple myeloma market, particularly for bispecific antibodies like teclistamab. | watch | 3-12m | 0.20 |
| 2026-09-26 | C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS | Indirect competitive landscape implications in multiple myeloma. | watch | 3-12m | 0.20 |
| 2026-09-24 | Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial | Increased competitive pressure in the kidney disease therapeutic area, potentially impacting future market share for existing or pipeline drugs. | Bearish | 3-12m | 0.25 |
| 2026-09-24 | Vertex Reports Positive Phase IIb Kidney Disease Data for Inaxaplin | Broad pharmaceutical company with existing presence in nephrology; potential for increased R&D focus or competitive response. | watch | 3-12m | 0.10 |
| 2026-09-23 | Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly | While not directly competing with GLP-1s, the success and expansion of the GLP-1 market, especially with oral options, could shift R&D focus and investor attention away from other metabolic or obesity-related drug pipelines, potentially impacting future market opportunities. | Bearish | 1-5y | 0.30 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide | Increased competitive landscape for next-generation obesity drugs, potentially diminishing the perceived value and market opportunity for Amgen's own pipeline assets (e.g., AMG 133). | Bearish | 3-12m | 0.50 |
| 2026-09-23 | Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide | Increased competitive pressure in the obesity drug market, potentially impacting the future market share and commercial viability of its own GLP-1 pipeline assets. | Bearish | 1-5y | 0.50 |
| 2026-09-23 | Novo Rebrands to 'Novo' and Deploys Oral GLP-1 Pill in Market Share Defense | Increased competitive pressure in the broader metabolic disease market, potentially impacting future pipeline products or existing drugs for related conditions. | Bearish | 3-12m | 0.40 |
| 2026-09-18 | Eli Lilly generates $27.7B in 1H GLP-1 sales as Foundayo gains PBM formulary | Increased competitive pressure in the obesity and metabolic disease space, potentially diverting R&D focus or market share from existing or pipeline products. | Bearish | 3-12m | 0.40 |
| 2026-09-18 | Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage | Intensified competition in the metabolic disease space, potentially diverting R&D focus and market attention from other therapeutic areas. | Bearish | 3-12m | 0.60 |
| 2026-09-18 | Eli Lilly GLP-1 Franchise Hits $27.7B in H1 2026 as Foundayo Gains PBM Coverage | Increased competitive pressure in the obesity/metabolic disease market, potentially impacting future pipeline assets or existing therapies. | Bearish | 1-5y | 0.50 |
| 2026-09-18 | Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands | Increased competition in the obesity/metabolic disease space, potentially diverting R&D resources or impacting future market share for pipeline drugs. | Bearish | 3-12m | 0.50 |
| 2026-09-18 | Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands | Increased competition in the obesity/metabolic disease space from highly effective GLP-1s, potentially diverting R&D focus or market share from Amgen's pipeline assets. | Bearish | 1-5y | 0.40 |
| 2026-09-18 | Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage | Increased competitive pressure in the obesity/metabolic disease market, potentially impacting the future market potential of Amgen's own GLP-1 pipeline candidates. | Bearish | 1-5y | 0.60 |
| 2026-09-17 | Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy | Increased competitive intensity in the GLP-1 market, potentially raising the bar for efficacy and market penetration for pipeline candidates. | watch | 3-12m | 0.40 |
| 2026-09-17 | Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways | Validation of novel therapeutic approaches, potential for future pipeline expansion or partnerships in cardiovascular diseases, especially given their existing cardiovascular portfolio. | Bullish | 1-3m | 0.65 |
| 2026-09-13 | Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY | Increased competitive intensity in the immunology market, potentially affecting market share and growth prospects for Amgen's immunology assets. | Bearish | 3-12m | 0.50 |
| 2026-09-13 | Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New Launches | Competitive landscape in the immunology market. LLY's strong immunology growth, particularly with Taltz (psoriasis/psoriatic arthritis), could pose a competitive challenge to AMGN's immunology assets like Otezla and Enbrel. | mixed | 3-12m | 0.50 |
| 2026-09-13 | Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1 | Indirect competitive pressure in the immunology market. LLY's expanding portfolio and strong performance could impact the broader competitive landscape. | mixed | 3-12m | 0.30 |
| 2026-09-13 | Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026 | Similar to J&J, Amgen faces direct competition in the immunology space. LLY's strong performance could signal a more challenging competitive landscape. | mixed | 3-12m | 0.40 |
| 2026-09-12 | Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New Labels | Increased competitive pressure in the immunology market, potentially affecting market share for drugs like Otezla and Enbrel. | mixed | 3-12m | 0.30 |
| 2026-09-12 | Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A Pipeline | Eli Lilly's expanding immunology portfolio and M&A activity could intensify competition for Amgen's immunology assets, potentially affecting future market share and growth prospects. | mixed | 3-12m | 0.40 |
| 2026-09-12 | Eli Lilly Immunology Division Generates $2.6B in H1 2026 Revenue | Competitive landscape in immunology; market share dynamics. | mixed | 3-12m | 0.50 |
| 2026-09-12 | Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A | Increased competitive dynamics in the immunology market, potentially impacting Amgen's existing immunology portfolio (e.g., Otezla, Enbrel) or future pipeline assets. | mixed | 3-12m | 0.30 |
| 2026-09-12 | Eli Lilly Immunology Revenue Reaches $2.6B in H1, Growing 9% Year-Over-Year | Increased competitive intensity in the immunology market from Eli Lilly's expanding portfolio, potentially affecting Amgen's immunology drug sales (e.g., Otezla, Enbrel) or requiring increased R&D/marketing spend. | mixed | 3-12m | 0.30 |
| 2026-09-12 | Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoY | Potential for increased competitive pressure in the immunology market. Amgen has a presence in immunology (e.g., Otezla, biosimilars to Humira), and Lilly's strong performance could signal a more crowded and competitive environment, potentially impacting Amgen's growth prospects in this therapeutic | mixed | 3-12m | 0.20 |
Continue this research
Build your Amgen Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the AMGN entity page →